Premium
K ATP Channel Pharmacogenomics: From Bench to Bedside
Author(s) -
Sattiraju S,
Reyes S,
Kane GC,
Terzic A
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100378
Subject(s) - pharmacogenomics , clinical pharmacology , pharmacology , pharmacodynamics , pharmacokinetics , potassium channel , drug discovery , drug , pharmacogenetics , herg , channelopathy , systems pharmacology , medicine , computational biology , bioinformatics , biology , neuroscience , gene , genetics , genotype
Inheritance plays a significant role in defining drug response and toxicity. Advances in molecular pharmacology and modern genomics emphasize genetic variation in dictating inter‐individual pharmacokinetics and pharmacodynamics. A case in point is the homeostatic ATP‐sensitive potassium (K ATP ) channel, an established drug target that adjusts membrane excitability to match cellular energetic demand. There is an increased recognition that genetic variability of the K ATP channel impacts therapeutic decision‐making in human disease. Clinical Pharmacology & Therapeutics (2008) doi: 10.1038/sj.clpt.6100378